HIV mutation literature information.


  Molecular basis of the association of H208Y and thymidine analogue resistance mutations M41L, L210W and T215Y in the HIV-1 reverse transcriptase of treated patients.
 PMID: 24667336       2014       Antiviral research
Abstract: Thymidine analogue resistance mutations (TAMs) in HIV-1 reverse transcriptase (RT) associate in two clusters: (i) TAM1 (M41L, L210W and T215Y) and TAM2 (D67N, K70R, K219E/Q, and sometimes T215F).


  Novel high-throughput screen identifies an HIV-1 reverse transcriptase inhibitor with a unique mechanism of action.
 PMID: 24969820       2014       The Biochemical journal
Abstract: HIV-1 resistance to zidovudine [AZT (azidothymidine)] is associated with selection of the mutations M41L, D67N, K70R, L210W, T215F/Y and K219Q/E in RT (reverse transcriptase).
Introduction: HIV-1 resistance to AZT is associated with selection of the thymidine analog mutations (TAMs) M41L, D67N, K70R, L210W, T215F/Y and K219Q/E in RT.
Result: Consistent with previously published data, we found that RTs


  HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia.
 PMID: 25141905       2014       Journal of the International AIDS Society
Introduction: There are two TAM pathways: type I (M41L, L210W and T215Y) and type II (D67N, K70R, T215F and K219Q/E); the former conferring higher levels of resistance and cross-resistance.
Result: A total of 35 patients had at least 1 TAM, with the following distribution: M41L (16%), D67N (15%), K70R (9%), L210W (11%), T215Y (16%), T215F (11%), K219Q (5%) and K219E (2%).


  Virological failure and HIV-1 drug resistance mutations among naive and antiretroviral pre-treated patients entering the ESTHER program of Calmette Hospital in Cambodia.
 PMID: 25166019       2014       PloS one
Result: The TAM2 pathway (D67N, K70R, T215F, and K219Q/E) was present in 5/22, 4/22, 8/22, 2/22 patients.


  Transmitted antiretroviral drug resistance mutations in newly diagnosed HIV-1 positive patients in Turkey.
 PMID: 25397495       2014       Journal of the International AIDS Society
Abstract: However, thymidine analogue resistance mutations (TAMs) determined two distinct genotypic profiles in the HIV-1 reverse transcriptase: TAM1: M41L, L210W and T215Y, and TAM2: D67N, K70R, K219E/Q, and T215F.


  Emergence of drug resistance in human immunodeficiency virus type 1 infected patients from pune, India, at the end of 12 months of first line antiretroviral therapy initiation.
 PMID: 25006528       2014       ISRN AIDS
Discussion: The type I pattern includes the mutations M41L, L210W, and T215Y while type II pattern includes D67N, K70R, T215F, and K219Q/E.


  Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.
 PMID: 23800377       2013       Retrovirology
Introduction: The excision reaction is facilitated by Excision Enhancement Mutations (EEMs), typically M41L, D67N, K70R, T215Y/F, L210W, and K219E/Q, which are also known as Thymidine Associated Mutations (TAMs) because they were historically linked to resistance to thymidine analogs AZT and d4T.


  HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana.
 PMID: 23977189       2013       PloS one
Table: K219Q


  Persistence of HIV-1 transmitted drug resistance mutations.
 PMID: 23904291       2013       The Journal of infectious diseases
Result: M41L was commonly observed and highly persistent (rate of loss 8 (95% CI, 4-15) per 100 PYFU), and a similar low rate of loss was seen for other TAMs (D67N, L210W, and K219Q/N); however, K70R appeared to be lost more quickly.
Result: NNRTI mutations appeared to be lost more quickly than most TAMs (M41L, D67N, L210W, and K219Q/N) and the 215 revertants (P < .001 for both comparisons).
Table: K219Q


  HIV-1 subtypes and primary antiretroviral resistance mutations in antiretroviral therapy naive HIV-1 infected individuals in Turkey.
 PMID: 23883841       2013       Japanese journal of infectious diseases
Abstract: The patients had primary antiretroviral resistance mutations to nucleos(t)ide reverse transcriptase (RT) inhibitors (NRTIs) (M41L, T215C, T215D, and K219Q), non-nucleoside RT inhibitors (NNRTIs; K103N), and protease inhibitors (PIs; I47V, G73S).



Browser Board

 Co-occurred Entities




   Filtrator